Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Anti-Arrhythmia Agents

Cardiotonic Agents

All Drugs and Chemicals

Antineoplastic Agents

Herbal and Botanical

Amino Acids

Digoxin

Erlotinib Hydrochloride

Tyrosine Kinase Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Protective Agents

Digitalis

Tyrosine

Each subject will receive erlotinib and digoxin daily until progression.

Erlotinib plus Digoxin

Goetz H Kloecker, MD, MSPH

The purpose of this study is to determine the potential benefit of adding Digoxin to erlotinib (Tarceva) treatment for patients with non-small cell lung cancer.

Non-small cell lung cancer (NSCLC) accounts for 80% of all lung cancer cases. The majority of NSCLC patients have advanced disease at the time of diagnosis, which usually requires treatment beyond standard first-line chemotherapy. Until recently, patients were limited in the number of options available for second-line treatment of NSCLC. In 2004, erlotinib was approved by the FDA for second and third-line treatment of NSCLC. Erlotinib is a cancer chemotherapy medication that slows the growth and spread of cancer cells in the body.

Recent research suggests that a medication called Digoxin can sensitize cancer cells to respond better to chemotherapy. Digoxin is normally used to treat certain heart conditions by helping the heart beat more strongly and regularly and is not approved by the FDA for the treatment of NSCLC. Investigators hope that subject response rates to standard erlotinib therapy will be significantly improved by the addition of Digoxin.

The purpose of this study is to determine the tumor response rate and overall survival of patients with non-small cell lung cancer treated with a daily regimen of erlotinib (Tarceva) plus Digoxin.

Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer

Phase II Trial of Second Line Erlotinib + Digoxin in Patients With Non-Small Cell Lung Cancer

James Graham Brown Cancer Center

University of Louisville

Associate Professor

Erlotinib plus Digoxin

Erlotinib plus Digoxin : Each subject will receive erlotinib and digoxin daily until progression.

Erlotinib and Digoxin

Age, Continuous

<=18 years

>18 years

Age, Customized

Sex: Female, Male

Dr. Goetz Kloecker

Partial Response

Stable Disease

Progressive Disease

Therapeutic Response, Evaluated by Computed Tomography (CT) Scans of Chest & Abdomen.

Overall Study

Spots Global Cancer Trial Database for erlotinib plus digoxin